Pharmaceutical

How AI is streamlining cell and gene therapy manufacturing

AI could deliver substantially greater efficiencies in cell and gene therapy manufacturing and enable more patients to benefit.

Feb 9, 2025 - 06:00
How AI is streamlining cell and gene therapy manufacturing
AI could deliver substantially greater efficiencies in cell and gene therapy manufacturing and enable more patients to benefit.
Read the original article

Tags:

Previous Article

Genentech eyes lupus market for Gazyva with positive Phase III data readout  

Next Article

Relmada acquires Tourette’s therapy rights from Asarina

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

MSD’s Keytruda wins expanded FDA combo approval in cervical cancer

MSD’s Keytruda wins expanded FDA combo approval in cerv...

Jan 15, 2024

Phase I completion of Sanofi’s vWD therapy demonstrates promise of pipeline

Phase I completion of Sanofi’s vWD therapy demonstrates...

May 16, 2023

Magenta Therapeutics and Dianthus agree to merge operations

Magenta Therapeutics and Dianthus agree to merge operat...

May 4, 2023